Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney…
NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). A class action lawsuit…
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.
Dubai, UAE, March 28, 2026 (GLOBE NEWSWIRE) -- Pepeto presale crossed $8.47 million after its latest presale round closed ahead of schedule, and the crypto news connecting this project to the BNB price prediction tells a story every BNB holder needs to understand.
Largo, FL, March 28, 2026 (GLOBE NEWSWIRE) -- This release reflects growing consumer discussions and publicly available information surrounding the viral "gelatin trick" trend in 2026. It is intended for informational purposes and does not represent independent product testing, evaluation, or third-party review of any product referenced. All product details described below are stated as…
